O-glycosylation of IgA1 and the Pathogenesis of an Autoimmune Disease IgA Nephropathy

Overview

Journal Glycobiology

Date 2024 Aug 2

PMID 39095059

Authors

Jan Novak

R Glenn King

Janet Yother

Matthew B Renfrow

Todd J Green

Affiliations

Soon will be listed here.

Abstract

IgA nephropathy is a kidney disease characterized by deposition of immune complexes containing abnormally O-glycosylated IgA1 in the glomeruli. Specifically, some O-glycans are missing galactose that is normally β1,3-linked to N-acetylgalactosamine of the core 1 glycans. These galactose-deficient IgA1 glycoforms are produced by IgA1-secreting cells due to a dysregulated expression and activity of several glycosyltransferases. Galactose-deficient IgA1 in the circulation of patients with IgA nephropathy is bound by IgG autoantibodies and the resultant immune complexes can contain additional proteins, such as complement C3. These complexes, if not removed from the circulation, can enter the glomerular mesangium, activate the resident mesangial cells, and induce glomerular injury. In this review, we briefly summarize clinical and pathological features of IgA nephropathy, review normal and aberrant IgA1 O-glycosylation pathways, and discuss the origins and potential significance of natural anti-glycan antibodies, namely those recognizing N-acetylgalactosamine. We also discuss the features of autoantibodies specific for galactose-deficient IgA1 and the characteristics of pathogenic immune complexes containing IgA1 and IgG. In IgA nephropathy, kidneys are injured by IgA1-containing immune complexes as innocent bystanders. Most patients with IgA nephropathy progress to kidney failure and require dialysis or transplantation. Moreover, most patients after transplantation experience a recurrent disease. Thus, a better understanding of the pathogenetic mechanisms is needed to develop new disease-specific treatments.

References

Novak J, Vu H, Novak L, Julian B, Mestecky J, Tomana M . Interactions of human mesangial cells with IgA and IgA-containing immune complexes. Kidney Int. 2002; 62(2):465-75. DOI: 10.1046/j.1523-1755.2002.00477.x. View

Gerken T, Jamison O, Perrine C, Collette J, Moinova H, Ravi L . Emerging paradigms for the initiation of mucin-type protein O-glycosylation by the polypeptide GalNAc transferase family of glycosyltransferases. J Biol Chem. 2011; 286(16):14493-507. PMC: 3077648. DOI: 10.1074/jbc.M111.218701. View

Fiskesund R, Steen J, Amara K, Murray F, Szwajda A, Liu A . Naturally occurring human phosphorylcholine antibodies are predominantly products of affinity-matured B cells in the adult. J Immunol. 2014; 192(10):4551-9. DOI: 10.4049/jimmunol.1303035. View

Green C . The ABO, Lewis and related blood group antigens; a review of structure and biosynthesis. FEMS Microbiol Immunol. 1989; 1(6-7):321-30. DOI: 10.1111/j.1574-6968.1989.tb02417.x. View

Storr S, Royle L, Chapman C, Abd Hamid U, Robertson J, Murray A . The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Glycobiology. 2008; 18(6):456-62. DOI: 10.1093/glycob/cwn022. View

Hansen J, Nielsen C, Arendrup M, Olofsson S, Mathiesen L, Nielsen J . Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus. J Virol. 1991; 65(12):6461-7. PMC: 250685. DOI: 10.1128/JVI.65.12.6461-6467.1991. View

Daniel E, Las Rivas M, Lira-Navarrete E, Garcia-Garcia A, Hurtado-Guerrero R, Clausen H . Ser and Thr acceptor preferences of the GalNAc-Ts vary among isoenzymes to modulate mucin-type O-glycosylation. Glycobiology. 2020; 30(11):910-922. PMC: 7581654. DOI: 10.1093/glycob/cwaa036. View

Sennhauser F, Hosking C, Jones C, Macdonald R, Mermelstein N, Roberton D . Anti-IgA antibodies in IgA-deficient children. J Clin Immunol. 1988; 8(5):356-61. DOI: 10.1007/BF00917151. View

Marglous S, Brown C, Padler-Karavani V, Cummings R, Gildersleeve J . Serum antibody screening using glycan arrays. Chem Soc Rev. 2024; 53(5):2603-2642. PMC: 7616341. DOI: 10.1039/d3cs00693j. View

10.

Putnam F, Liu Y, Low T . Primary structure of a human IgA1 immunoglobulin. IV. Streptococcal IgA1 protease, digestion, Fab and Fc fragments, and the complete amino acid sequence of the alpha 1 heavy chain. J Biol Chem. 1979; 254(8):2865-74. View

11.

Hansen J, Clausen H, Nielsen C, Teglbjaerg L, Hansen L, Nielsen C . Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization. J Virol. 1990; 64(6):2833-40. PMC: 249465. DOI: 10.1128/JVI.64.6.2833-2840.1990. View

12.

Baenziger J, Kornfeld S . Structure of the carbohydrate units of IgA1 immunoglobulin. I. Composition, glycopeptide isolation, and structure of the asparagine-linked oligosaccharide units. J Biol Chem. 1974; 249(22):7260-9. View

13.

Brandtzaeg P . Transport models for secretory IgA and secretory IgM. Clin Exp Immunol. 1981; 44(2):221-32. PMC: 1537350. View

14.

Muthana S, Gildersleeve J . Factors Affecting Anti-Glycan IgG and IgM Repertoires in Human Serum. Sci Rep. 2016; 6:19509. PMC: 4726023. DOI: 10.1038/srep19509. View

15.

Floege J . Recurrent IgA nephropathy after renal transplantation. Semin Nephrol. 2004; 24(3):287-91. DOI: 10.1016/j.semnephrol.2004.01.008. View

16.

Kiryluk K, Moldoveanu Z, Sanders J, Eison T, Suzuki H, Julian B . Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. Kidney Int. 2011; 80(1):79-87. PMC: 3641561. DOI: 10.1038/ki.2011.16. View

17.

Woof J, Kerr M . The function of immunoglobulin A in immunity. J Pathol. 2005; 208(2):270-82. DOI: 10.1002/path.1877. View

18.

Mayr J, Lau K, Lai J, Gagarinov I, Shi Y, McAtamney S . Unravelling the Role of O-glycans in Influenza A Virus Infection. Sci Rep. 2018; 8(1):16382. PMC: 6219607. DOI: 10.1038/s41598-018-34175-3. View

19.

Allen A, Harper S, Feehally J . Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol. 1995; 100(3):470-4. PMC: 1534466. DOI: 10.1111/j.1365-2249.1995.tb03724.x. View

20.

Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr A, Renfrow M . The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011; 22(10):1795-803. PMC: 3892742. DOI: 10.1681/ASN.2011050464. View